Lyo Container Closure Systems

Container Closure Systems for Freeze-Dried Products

4K microstructure render of a DigiM pharmaceutical sample showing internal phase composition at high resolution
Full field-of-view pharmaceutical tablet microstructure image showing internal phase distribution and pore network

Assessing the impact of container closure systems on primary drying efficiency and lyophilized drug product quality

Container closure systems (CCS) play an essential role in maintaining drug product quality over time. For freeze-dried products, the CCS can also affect the heat and mass transfer during lyophilization and the ultimate primary drying efficiency. As a result, the CCS plays an important role in product quality and process selection. If the CCS is changed, additional adjustments in the freeze-drying process may be required to optimize the drug product.

Assessment of lyophilization primary drying efficiency and container closure systems
Lyophilized samples in two glass vials with different heat transfer parameters were investigated with multi-scale XRM imaging.

In this study, a systematic evaluation was conducted to understand how container closure system variables affect lyophilization formulation characteristics and freeze-drying process parameters. In addition, the vial position in the  freeze-dryer was considered in terms of its potential risk on process failure with different CCS. The evaluated CCS variables were glass vial dimensions and manufacturer, while the evaluated formulation variables were concentration of biologic drug substance, total solid content, and fill height. In addition, freezing process such as conventional freezing or controlled ice nucleation and primary drying parameters were studied in the context of the potential risk to process and product failure. The results revealed that changing the CCS of freeze-dried products without adjustments  in the freeze-drying process parameters may lead to a loss in process efficiency and product quality.

AbbVie logo
AbbVie logo
Bausch Health logo
Bausch Health logo
Bristol Myers Squibb logo
Bristol Myers Squibb logo
Merck logo
Merck logo
Moderna logo
Moderna logo
Novartis logo
Novartis logo
Pfizer logo
Pfizer logo
Johnson & Johnson Innovative Medicine logo
Johnson & Johnson Innovative Medicine logo
Roche logo
Roche logo
Mirati Therapeutics logo
Mirati Therapeutics logo
Genentech logo
Genentech logo
Lonza logo
Lonza logo
AbbVie logo
AbbVie logo
Bausch Health logo
Bausch Health logo
Bristol Myers Squibb logo
Bristol Myers Squibb logo
Merck logo
Merck logo
Moderna logo
Moderna logo
Novartis logo
Novartis logo
Pfizer logo
Pfizer logo
Johnson & Johnson Innovative Medicine logo
Johnson & Johnson Innovative Medicine logo
Roche logo
Roche logo
Mirati Therapeutics logo
Mirati Therapeutics logo
Genentech logo
Genentech logo
Lonza logo
Lonza logo

Our Expertise

In Numbers

95
+
%

Programs Supported

981
+
%

Formulations Digitized

22
+
%

Pharmaceutical Partners

Stats section background image for DigiM Solution website showing pharmaceutical data visualization context

Transform Your Program with Microstructure Science

Get started with a drug product digital twin.

A purple tablet dissolving